Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis

References

• Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72:247–259.
   PubMed Web of Science ®Google Scholar
• Saran R, Li Y, Robinson B, et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the united states. Am J Kidney Dis. 2015; 66:S1–S305.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379:815–822.
   PubMed Web of Science ®Google Scholar
• Sud M, Tangri N, Pintilie M, Levey AS, et al. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation. 2014;130:458–465.
   PubMedGoogle Scholar
• Gansevoort RT, Correa- Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382:339–352.
   PubMed Web of Science ®Google Scholar
• Braun L, Sood V, Hogue S, et al. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151–163.
   PubMedGoogle Scholar
• Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55:441–451.
   PubMed Web of Science ®Google Scholar
• Janssen WM, de Jong PE, de Zeeuw D. Hypertension and renal disease: role of microalbuminuria. J Hypertens Suppl. 1996;14:S173–S177.
   PubMedGoogle Scholar
• El Minshawy O, Ghabrah T, El Bassuoni E. Diabetic nephropathy as a cause of end-stage renal disease in Tabuk area, Saudi Arabia: a four-year study. Saudi. Saudi J Kidney Dis Transpl. 2014;25:1105–1109.
   PubMedGoogle Scholar
• Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001; 24:691–697.
   PubMed Web of Science ®Google Scholar
• Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796–803.
   PubMed Web of Science ®Google Scholar
• Higgins J, Altman DG. Assessing risk of bias istudies. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford: Cochrane Collaboration, 2008.
   Google Scholar
• Follmann D, Elliott P, Suh I, et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45:769–773.
   PubMed Web of Science ®Google Scholar
• Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–59.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–1393.
   PubMed Web of Science ®Google Scholar
• Momeni A, Shahidi S, Seirafian S, et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis. 2010;4:128–132.
   PubMed Web of Science ®Google Scholar
• Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011; 22:1382–1389.
   PubMed Web of Science ®Google Scholar
• Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153–160.
   PubMed Web of Science ®Google Scholar
• Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-Month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66:945–950.
   PubMed Web of Science ®Google Scholar
• Liu J, Sheng D. Allopurinol in lowering serum uric acid level for the delay of the progression of chronic renal disease. China Pharm. 2007;18:2524–2525.
   Google Scholar
• Lei J, Li ST. Clinical research on allopurinol lowering of uric acid level of chronic renal disease for the delay of the progression of renal disease. Shanxi Med J. 2009; 38:1191–1192.
   Google Scholar
• Zhou DY, Zhao YJ, Xiao X, et al. Treatment of hyperuricemia in chronic kidney disease patients and its effect. Mod Med J China (Chinese). 2009; 11:36–39.
   Google Scholar
• Deng YH, Zhang P, Liu H, et al. Observation on allopurinol in lowering blood uric acid for slowing the progression of chronic renal failure. J Pract Med. 2010;26:982–984.
   Google Scholar
• Shen H, Liu D. Clinical research on allopurinol in lowering serum uric acid level for the delay of the progression of chronic renal disease. China Foreign Med Treat. 2010;12:88–89.
   Google Scholar
• Tan Y, Fu JZ, Liang M, et al. Clinical observation of the effect of allopurinol to protect renal function in patients with diabetic nephropathy. Mod Hosp. 2011;11:36–38.
   Google Scholar
• Sedaghat S, Hoorn EJ, van Rooij FJA, et al. Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One. 2013;8:e76827.
   PubMed Web of Science ®Google Scholar
• Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant. 2003; 18:664–669.
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991–F997.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283: F1105–F1110.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295:F1134–F1141.
   PubMed Web of Science ®Google Scholar
• Diwan V, Mistry A, Gobe G, et al. Adenine-induced chronic kidney and cardiovascular damage in rats. J Pharmacol Toxicol Methods. 2013;68:197–207.
   PubMed Web of Science ®Google Scholar
• Murali NS, Ackerman AW, Croatt AJ, et al. Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease. Am J Physiol Renal Physiol. 2007;292:F837–F844.
   PubMed Web of Science ®Google Scholar
• Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36:43–49.
   PubMed Web of Science ®Google Scholar
• Alshahawey M, Shahin SM, Elsaid TW, et al. Effect of febuxostat on the endothelial dysfunction in hemodialysis patients: a randomized, placebo-controlled, double-blinded study. Am J Nephrol. 2017; 45:452–459.
   PubMed Web of Science ®Google Scholar
• Kim IY, Lee DW, Lee SB, et al. The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship. Biomed Res Int. 2014;2014:638732.
   PubMedGoogle Scholar
• Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406–413.
   PubMed Web of Science ®Google Scholar
• Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58.
   PubMed Web of Science ®Google Scholar
• Ye P, Yang S, Zhang W, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35:180–189.
   PubMed Web of Science ®Google Scholar
• Benedict JD, Forsham PH, Roche M, et al. effect of salicylates and adrenocorticotropic hormone upon the miscible pool of uric acid in gout. J Clin Invest. 1950;29:1104–1111.
   PubMed Web of Science ®Google Scholar
• Scott JT, Holloway VP, Glass HI, et al. Studies of uric acid pool size and turnover rate. Ann Rheum Dis. 1969;28:366–373.
   PubMed Web of Science ®Google Scholar